FDA Reviews Samsung Bioepis’ Bevacizumab
Avastin Rival Will Be Sold Through Merck, Sharp & Dohme
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
You may also be interested in...
Mylan and Biocon's global development alliance has so far led to two biosimilar launches in the US. A filing for a biosimilar of Genentech's Avastin (bevacizumab) submitted by Mylan may soon bring a third.
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.
Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.